Results 1 to 10 of about 89,818 (264)

JAK Inhibitor and Crohn’s Disease [PDF]

Biomedicines
Crohn’s disease is a chronic inflammatory granulomatous disease of the gastrointestinal tract. The global incidence and prevalence of Crohn’s disease have significantly increased, largely due to genetic susceptibility, environmental changes, and ...
Mengyan Xu, Shi Wang, Sanping Xu, Rui Gong   +3 more
doaj   +4 more sources

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis [PDF]

Journal of Immunotherapy and Precision Oncology, 2021
Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia.
Andrew T. Kuykendall, Rami S. Komrokji
doaj   +4 more sources

Topical JAK inhibitor for refractory skin inflammation in STAT1 GOFTopical JAK inhibitor in STAT1 GOF [PDF]

Journal of Human Immunity
Topical ruxolitinib induced rapid and sustained improvement of refractory skin inflammation in a child with STAT1 GOF disease, highlighting its potential in managing localized inflammation in immune dysregulation.
Valentina Guarnieri, Tiphaine Arlabosse, Claire Booth, Gabriela Petrof   +3 more
doaj   +2 more sources

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti‐MDA5 Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study [PDF]

ACR Open Rheumatology
Objective To evaluate the clinical characteristics and serum cytokine profiles of patients with anti‐MDA5 antibody–positive dermatomyositis with interstitial lung disease (MDA5+ DM‐ILD) treated with JAK inhibitors and to compare survivors and ...
Haruna Matsuo, Tomohiro Koga, Toshimasa Shimizu, Hiroyuki Ide, Serina Koto, Kanako Kojima, Yuya Fujita, Momoko Okamoto, Ayuko Takatani, Takahisa Suzuki, Yuta Matsushita, Atsushi Kawakami   +11 more
doaj   +2 more sources

Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors

Allergology International, 2022
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. The knowledge on the pathogenesis of AD is driving the development of new drugs. From the research results, it has been revealed that Th2 cell-mediated immunity,
Chisa Nakashima, Shigeto Yanagihara, Atsushi Otsuka   +2 more
doaj   +1 more source

JAK inhibition ameliorates bone destruction by simultaneously targeting mature osteoclasts and their precursors

Inflammation and Regeneration, 2023
Background Rheumatoid arthritis (RA) is characterized by chronic inflammation and resultant cartilage/bone destruction because of aberrantly activated osteoclasts.
Shinya Yari, Junichi Kikuta, Hotaka Shigyo, Yu Miyamoto, Daisuke Okuzaki, Yuki Furusawa, Masafumi Minoshima, Kazuya Kikuchi, Masaru Ishii   +8 more
doaj   +1 more source

Tofacitinib

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical ...
Nilgün Şentürk
doaj   +1 more source

Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss

Inflammation and Regeneration, 2023
Background The types of bone damage in rheumatoid arthritis (RA) include joint erosion, periarticular osteoporosis, and systemic osteoporosis. Janus kinase (JAK) inhibitors ameliorate inflammation and joint erosion in RA, but their effect on the three ...
Masatsugu Komagamine, Noriko Komatsu, Rui Ling, Kazuo Okamoto, Shi Tianshu, Kotaro Matsuda, Tsutomu Takeuchi, Yuko Kaneko, Hiroshi Takayanagi   +8 more
doaj   +1 more source

Insights, current status and future perspective of JAK inhibitors in the treatment of alopecia areata

Pifu-xingbing zhenliaoxue zazhi, 2022
Alopecia areata (AA) is a chronic heterogeneous inflammatory disease, with unknown pathogenesis. Although there are quite a few options to choose for treatment of AA, there is no specific therapic method, and neither is one therapic method for all ...
Xingqi ZHANG
doaj   +1 more source

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies

Immunological Medicine, 2023
Recent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD).
Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima   +2 more
doaj   +1 more source